Home・Akciju saraksts・Compugen Ltd

Compugen Ltd

Slēgts

1.91 -5.45

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.98

Max

2.04

Galvenie mērījumi
By Trading Economics
Ienākumi	663K -7M
Pārdošana	426K 2.6M
P/E Sektora vidējais	5.211 51.78
EPS	-0.07
Peļņas marža	-269.254
Darbinieki	75
EBITDA	665K -7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+123.88% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 9. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-38M 188M
Iepriekšējā atvēršanas cena	7.36
Iepriekšējā slēgšanas cena	1.91

Compugen Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. nov. 23:56 UTC

KBR Inc shares are down significantly in after-market trading, falling to their lowest point of the day.

2026. g. 4. nov. 23:56 UTC

News

Social Media

Trimble Inc appoints Matthew C. Brown, former CFO of Tenable Holdings, to its Board of Directors in after-market trading.

2026. g. 4. nov. 23:56 UTC

Correlated Moves

D.R. Horton, Inc. shares traded modestly lower in after-market hours, while Amcor PLC's sharp decline followed disappointing Q1 results and lowered EPS guidance.

2026. g. 4. nov. 23:56 UTC

Hims & Hers Health, Inc. is trading modestly higher in after-market hours following an increase during the session.

2026. g. 4. nov. 23:56 UTC

Correlated Moves

Lattice Semiconductor Corporation shares declined in after-market trading, continuing a downward trend since Wednesday's close and nearing the lower end of their one-month range.

2026. g. 4. nov. 23:56 UTC

IES Holdings Inc shares rose significantly during after-market hours on Wednesday, recovering from a recent decline and moving higher following the close of regular trading.

2026. g. 4. nov. 23:56 UTC

Synopsys, Inc. shares are trading modestly higher in after-market hours, recovering from earlier lows after four consecutive daily declines.

2026. g. 4. nov. 23:52 UTC

News

Uranium Energy Corp. is trading modestly higher in after-market hours following fluctuations since Wednesday's close.

2026. g. 4. nov. 23:51 UTC

Kontoor Brands, Inc. is trading lower in after-market hours, retreating from a brief uptick and remaining at the lower end of its recent range.

2026. g. 4. nov. 23:51 UTC

GE HealthCare Technologies Inc. is trading modestly higher in after-market hours, despite a slight decline from earlier session highs.

2026. g. 4. nov. 23:51 UTC

Mondelez International, Inc. shares have advanced modestly in after-market hours, remaining near the upper end of their one-month range.

2026. g. 4. nov. 23:51 UTC

Avient Corp is declining in after-market trading, falling to its lowest point of the day.

2026. g. 4. nov. 23:51 UTC

Lindsay Corporation's shares traded modestly lower during after-market hours on Wednesday, remaining around the midpoint of their one-month trading range.

2026. g. 4. nov. 23:51 UTC

News

Watts Water Technologies reports Q3 net sales of $728 million, exceeding estimates, with diluted EPS of $4.34 and raises full-year sales growth outlook to 17%-18%.

2026. g. 4. nov. 23:51 UTC

Twist Bioscience Corporation shares declined during after-market hours on Wednesday, reversing a trend of higher daily closes observed in recent sessions.

2026. g. 4. nov. 23:51 UTC

Wendy's Co shares are declining in after-market trading, reflecting pronounced losses despite a strong recent performance and seven consecutive sessions of higher closes.

2026. g. 4. nov. 23:51 UTC

Delta Air Lines, Inc. shares are trading lower in after-market hours, pulling back from earlier gains.

2026. g. 4. nov. 23:51 UTC

Correlated Moves

Clorox Company shares are modestly lower in after-market trading, following a brief peak earlier in the session.

2026. g. 4. nov. 23:51 UTC

BlackRock, Inc. shares traded modestly lower in after-market hours, retracing from an early session peak.

2026. g. 4. nov. 23:51 UTC

Correlated Moves

Vertiv Holdings Co is modestly higher in after-market trading, moving in sympathy with Eaton Corporation PLC following strong third-quarter results.

2026. g. 4. nov. 23:51 UTC

Redwood Trust, Inc. shares declined during after-market trading on Wednesday, moving notably lower from a modest high shortly after the market closed.

2026. g. 4. nov. 23:46 UTC

News

Correlated Moves

Chord Energy reports Q3 adjusted EPS of $6.08, exceeding estimates, while revenues of $1.71B missed expectations; raises 2026 adjusted EBITDA guidance to $3.4B.

2026. g. 4. nov. 23:46 UTC

Martin Marietta Materials, Inc. is trading modestly higher in after-market hours, reaching its highest level since Wednesday's close and above its 20-day moving average.

2026. g. 4. nov. 23:46 UTC

ZIM Integrated Shipping Services Ltd is trading lower in after-market hours, continuing its downward trend from Wednesday's close and positioned 3.49% below its 20-day moving average.

2026. g. 4. nov. 23:46 UTC

News

UBS maintains Neutral rating on Coca-Cola Europacific Partners PLC and raises price target to $115 in a report published after the market closed.

2026. g. 4. nov. 23:46 UTC

The NZD/CAD is trading modestly higher, supported by stronger-than-expected ADP Employment Change data, which reported an increase of 86k jobs in October.

2026. g. 4. nov. 23:46 UTC

GBP/NZD is lower, reflecting a decline since Tuesday's close.S. employment and services data.

2026. g. 4. nov. 23:46 UTC

Arbor Realty Trust, Inc. traded roughly flat in after-market hours, remaining near the lower end of its one-month range and below its 20-day moving average.

2026. g. 4. nov. 23:42 UTC

Lincoln Electric Holdings, Inc. is trading lower in after-market hours, reversing an initial gain and marking a fourth consecutive daily decline.

2026. g. 4. nov. 23:42 UTC

Alector, Inc. is declining sharply in after-market trading, reaching its lowest point of the day after previously showing strength above its 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Compugen Ltd Prognoze

Cenas mērķis

By TipRanks

123.88% augšup

Prognoze 12 mēnešiem

Vidējais 4.5 USD 123.88%

Augstākais 6 USD

Zemākais 4 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Compugen Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Compugen Ltd — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.